Research status and hotspot analysis of acute exacerbation of chronic obstructive pulmonary disease based on bibliometrics_West China Medical Journal

Authors：

JIA Mingyan ^1,2,3 , XIE Kai ^1,2,3 ,  WANG Haifeng ^1,2,3

1. National Regional Traditional Chinese Medicine (Lung Disease) Diagnosis and Treatment Center, the First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan 450000, P. R. China;
2. The First Clinical Medical College of Henan University of CM, Zhengzhou, Henan 450000, P. R. China;
3. Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of China, Zhengzhou, Henan 450046, P. R. China;

Corresponding?author：

WANG Haifeng, Email: wangh_f@126.com

Keywords：

Acute exacerbation of chronic obstructive pulmonary disease; bibliometrics; research progress; hotspot analysis; CiteSpace

DOI：

10.7507/1002-0179.202501180

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze and summarize the research status, hotspots, and development trends in the field of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods The AECOPD-related literature from 2013 to 2023 was retrieved from the China National Knowledge Infrastructure and Web of Science. Based on bibliometric methods, CiteSpace 6.2.R2 and Excel software were used to analyze the journals, authors, institutions, and keywords of AECOPD-related Chinese and English literature. Results Finally, 802 Chinese literature and 3478 English literature were included. The number of Chinese studies on AECOPD had shown a relatively stable trend in the past decade. The number of English studies on AECOPD showed a fluctuating upward trend, reaching its peak in 2021 and then slightly decreasing. The overall number of studies showed a fluctuating upward trend. Compared to Chinese literature authors, English literature authors collaborated more closely. Prior to 2017, Chinese literature mainly focused on the inflammatory mechanisms, bacterial infections, and antibiotic treatment of AECOPD. From 2017 to 2023, attention had been paid to bacterial resistance, traditional Chinese medicine syndrome types, influencing factors, and prognostic nursing. The pathogenesis of inflammation continued to be closely monitored, while also paying attention to oxidative stress mechanisms. The English literature from 2013 to 2018 mainly focused on the clinical outcomes, clinical trials, pathological studies, and antibiotic treatment of AECOPD, with a particular emphasis on its comorbidities with cardiovascular diseases such as myocardial infarction. From 2019 to 2023, the main focus was on the global burden and medical insurance utilization of AECOPD, as well as its pathogenesis, with a particular emphasis on micro level research on the lung microbiome and cell related aspects. Conclusion At present, the publication volume of AECOPD topics is showing a fluctuating upward trend, the disciplinary fields are constantly expanding, and research hotspots are constantly moving forward, receiving widespread attention both domestically and internationally. The overall development trend of related research is good, and cooperation should be strengthened to conduct more in-depth research.

Citation： JIA Mingyan, XIE Kai, WANG Haifeng. Research status and hotspot analysis of acute exacerbation of chronic obstructive pulmonary disease based on bibliometrics. West China Medical Journal, 2026, 41(1): 72-78. doi: 10.7507/1002-0179.202501180 Copy

1.	GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, 5(9): 691-706.
2.	Han W, Wang M, Xie Y, et al. Prevalence of pulmonary embolism and deep venous thromboembolism in patients with acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Front Cardiovasc Med, 2022, 9: 732855.
3.	Fang H, Zhang H, Wang Z, et al. Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture. J Clin Lab Anal, 2020, 34(1): e23016.
4.	Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J, 2018, 52(5): 1801261.
5.	尹美玲, 孫曉媛, 岳利峰, 等. 基于文獻計量學的國內外睡眠障礙研究現狀與熱點分析. 世界科學技術-中醫藥現代化, 2022, 24(1): 436-445.
6.	Yao L, Hui L, Yang Z, et al. Freshwater microplastics pollution: detecting and visualizing emerging trends based on Citespace II. Chemosphere, 2020, 245: 125627.
7.	馮貞貞, 何雯青, 謝洋, 等. 慢性阻塞性肺疾病急性加重期證候療效評價量表初步研制. 中國中西醫結合雜志, 2023, 43(5): 564-571.
8.	何雯青, 馮貞貞, 春柳, 等. 慢性阻塞性肺疾病急性加重期證候療效評價要素研究——基于文獻研究結合專家咨詢. 中醫雜志, 2022, 63(5): 481-487.
9.	王至婉, 李羚, 李建生, 等. 基于貝葉斯網絡的慢性阻塞性肺疾病急性加重期證候與癥狀間的關聯模式. 中華中醫藥雜志, 2019, 34(9): 3964-3969.
10.	王露, 張海龍, 張東, 等. 中藥治療慢性阻塞性肺疾病急性加重系統評價/Meta 分析的質量評價. 中國老年學雜志, 2021, 41(14): 2968-2972.
11.	謝洋, 王佳佳, 李宣霖, 等. 針刺治療慢性阻塞性肺疾病急性加重期的臨床研究文獻分析. 中國老年學雜志, 2019, 39(13): 3151-3154.
12.	王明航, 畢麗嬋, 趙歡歡, 等. 慢性阻塞性肺疾病急性加重再入院影響因素. 中國老年學雜志, 2022, 42(13): 3354-3356.
13.	王明航, 陳學昂, 李曉俊, 等. 基于臨床研究數據的慢性阻塞性肺疾病急性加重風險因素的篩選. 中華中醫藥雜志, 2019, 34(10): 4839-4846.
14.	Bhatt SP, Agusti A, Bafadhel M, et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2023, 208(10): 1026-1041.
15.	Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med, 2014, 189(12): 1503-1508.
16.	Bhatt SP, Connett JE, Voelker H, et al. β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open, 2016, 6(6): e012292.
17.	Singh D, Criner GJ, Dransfield MT, et al. Informing the pathway of COPD treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res, 2021, 22(1): 130.
18.	Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med, 2017, 5(8): 619-626.
19.	Leitao Filho FS, Mattman A, Schellenberg R, et al. Serum IgG levels and risk of COPD hospitalization a pooled meta-analysis. Chest, 2020, 158(4): 1420-1430.
20.	Crisan L, Wong N, Sin DD, et al. Karma of cardiovascular disease risk factors for prevention and management of major cardiovascular events in the context of acute exacerbations of chronic obstructive pulmonary disease. Front Cardiovasc Med, 2019, 6: 79.
21.	Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. a post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med, 2018, 198(1): 51-57.
22.	Dransfield MT, Criner GJ, Halpin D, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc, 2022, 11(18): e24350.
23.	Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Respirology, 2023, 28(4): 316-338.
24.	Du X, Chen Y, Zhang R, et al. Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Front Pharmacol, 2024, 15: 1466677.
25.	宋衛珍, 董凌云. 噻托溴銨吸入劑聯合布地奈德福莫特羅治療對老年急性加重期 COPD 患者肺功能及對 HMGB1、Copeptin 的影響. 中國老年學雜志, 2020, 40(9): 1847-1851.
26.	何淑霞, 俞峭拔, 孫小麗, 等. 硫酸沙丁胺醇聯合噻托溴銨治療慢性阻塞性肺疾病急性加重期患者的臨床研究. 中國臨床藥理學雜志, 2020, 36(12): 1606-1609.
27.	Wang Y, Ninaber DK, Faiz A, et al. Acute cigarette smoke exposure leads to higher viral infection in human bronchial epithelial cultures by altering interferon, glycolysis and GDF15-related pathways. Respir Res, 2023, 24(1): 207.
28.	Liu P, Gao H, Wang Y, et al. LncRNA H19 contributes to smoke-related chronic obstructive pulmonary disease by targeting miR-181/PDCD4 axis. COPD, 2023, 20(1): 119-125.
29.	Golpe R, Blanco-Cid N, Dacal-Rivas D, et al. Incidence and profile of severe exacerbations of chronic obstructive pulmonary disease due to biomass smoke or tobacco. Ann Thorac Med, 2022, 17(4): 193-198.
30.	Xu Z, Li F, Xin Y, et al. Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis. Respir Res, 2024, 25(1): 410.
31.	付玉芬, 牟婷, 何翔, 等. 慢性阻塞性肺疾病頻繁急性加重的危險因素分析和預測模型構建. 中國醫學科學院學報, 2024, 46(4): 519-527.
32.	Francis NA, Gillespie D, White P, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT. Health Technol Assess, 2020, 24(15): 1-108.
33.	胡小燕, 徐鑲懷, 鄭曉, 等. 血清內皮細胞特異性分子 1 與降鈣素原聯合檢測在慢性阻塞性肺疾病急性加重細菌感染中的臨床意義. 海軍軍醫大學學報, 2023, 44(8): 989-993.
34.	劉丹, 范惠君, 武亞莉, 等. 不同通氣方式對急性加重慢性阻塞性肺疾病患者呼吸道病毒分布及預后的影響. 中國病原生物學雜志, 2021, 16(7): 822-825.
35.	方晗語, 陳琳雯, 馮沁祺, 等. 基于 VOSviewer 軟件的中醫藥治療慢性阻塞性肺疾病急性加重期文獻計量學分析. 中國中醫基礎醫學雜志, 2022, 28(2): 243-246, 259.
36.	陳艷, 李曉梅. 老年 COPD 患者急性加重期并發呼吸衰竭危險因素及風險模型構建. 中國老年學雜志, 2022, 42(22): 5478-5480.
37.	Marriott E, Singanayagam A, El-Awaisi J. Inflammation as the nexus: exploring the link between acute myocardial infarction and chronic obstructive pulmonary disease. Front Cardiovasc Med, 2024, 11: 1362564.
38.	Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med, 2020, 41(3): 421-438.
39.	余群, 歐陽麗. 痰熱清注射液對痰濁壅肺型慢性阻塞性肺疾病急性加重期患者肺血管阻力和氧化應激指標的影響. 中國中醫基礎醫學雜志, 2019, 25(10): 1380-1382, 1403.
40.	Yu S, Zhang H, Wan L, et al. The association between the respiratory tract microbiome and clinical outcomes in patients with COPD. Microbiol Res, 2023, 266: 127244.
41.	Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease. Respir Res, 2019, 20(1): 113.

1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, 5(9): 691-706.
2. Han W, Wang M, Xie Y, et al. Prevalence of pulmonary embolism and deep venous thromboembolism in patients with acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Front Cardiovasc Med, 2022, 9: 732855.
3. Fang H, Zhang H, Wang Z, et al. Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture. J Clin Lab Anal, 2020, 34(1): e23016.
4. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J, 2018, 52(5): 1801261.
5. 尹美玲, 孫曉媛, 岳利峰, 等. 基于文獻計量學的國內外睡眠障礙研究現狀與熱點分析. 世界科學技術-中醫藥現代化, 2022, 24(1): 436-445.
6. Yao L, Hui L, Yang Z, et al. Freshwater microplastics pollution: detecting and visualizing emerging trends based on Citespace II. Chemosphere, 2020, 245: 125627.
7. 馮貞貞, 何雯青, 謝洋, 等. 慢性阻塞性肺疾病急性加重期證候療效評價量表初步研制. 中國中西醫結合雜志, 2023, 43(5): 564-571.
8. 何雯青, 馮貞貞, 春柳, 等. 慢性阻塞性肺疾病急性加重期證候療效評價要素研究——基于文獻研究結合專家咨詢. 中醫雜志, 2022, 63(5): 481-487.
9. 王至婉, 李羚, 李建生, 等. 基于貝葉斯網絡的慢性阻塞性肺疾病急性加重期證候與癥狀間的關聯模式. 中華中醫藥雜志, 2019, 34(9): 3964-3969.
10. 王露, 張海龍, 張東, 等. 中藥治療慢性阻塞性肺疾病急性加重系統評價/Meta 分析的質量評價. 中國老年學雜志, 2021, 41(14): 2968-2972.
11. 謝洋, 王佳佳, 李宣霖, 等. 針刺治療慢性阻塞性肺疾病急性加重期的臨床研究文獻分析. 中國老年學雜志, 2019, 39(13): 3151-3154.
12. 王明航, 畢麗嬋, 趙歡歡, 等. 慢性阻塞性肺疾病急性加重再入院影響因素. 中國老年學雜志, 2022, 42(13): 3354-3356.
13. 王明航, 陳學昂, 李曉俊, 等. 基于臨床研究數據的慢性阻塞性肺疾病急性加重風險因素的篩選. 中華中醫藥雜志, 2019, 34(10): 4839-4846.
14. Bhatt SP, Agusti A, Bafadhel M, et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2023, 208(10): 1026-1041.
15. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med, 2014, 189(12): 1503-1508.
16. Bhatt SP, Connett JE, Voelker H, et al. β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open, 2016, 6(6): e012292.
17. Singh D, Criner GJ, Dransfield MT, et al. Informing the pathway of COPD treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res, 2021, 22(1): 130.
18. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med, 2017, 5(8): 619-626.
19. Leitao Filho FS, Mattman A, Schellenberg R, et al. Serum IgG levels and risk of COPD hospitalization a pooled meta-analysis. Chest, 2020, 158(4): 1420-1430.
20. Crisan L, Wong N, Sin DD, et al. Karma of cardiovascular disease risk factors for prevention and management of major cardiovascular events in the context of acute exacerbations of chronic obstructive pulmonary disease. Front Cardiovasc Med, 2019, 6: 79.
21. Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. a post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med, 2018, 198(1): 51-57.
22. Dransfield MT, Criner GJ, Halpin D, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc, 2022, 11(18): e24350.
23. Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Respirology, 2023, 28(4): 316-338.
24. Du X, Chen Y, Zhang R, et al. Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Front Pharmacol, 2024, 15: 1466677.
25. 宋衛珍, 董凌云. 噻托溴銨吸入劑聯合布地奈德福莫特羅治療對老年急性加重期 COPD 患者肺功能及對 HMGB1、Copeptin 的影響. 中國老年學雜志, 2020, 40(9): 1847-1851.
26. 何淑霞, 俞峭拔, 孫小麗, 等. 硫酸沙丁胺醇聯合噻托溴銨治療慢性阻塞性肺疾病急性加重期患者的臨床研究. 中國臨床藥理學雜志, 2020, 36(12): 1606-1609.
27. Wang Y, Ninaber DK, Faiz A, et al. Acute cigarette smoke exposure leads to higher viral infection in human bronchial epithelial cultures by altering interferon, glycolysis and GDF15-related pathways. Respir Res, 2023, 24(1): 207.
28. Liu P, Gao H, Wang Y, et al. LncRNA H19 contributes to smoke-related chronic obstructive pulmonary disease by targeting miR-181/PDCD4 axis. COPD, 2023, 20(1): 119-125.
29. Golpe R, Blanco-Cid N, Dacal-Rivas D, et al. Incidence and profile of severe exacerbations of chronic obstructive pulmonary disease due to biomass smoke or tobacco. Ann Thorac Med, 2022, 17(4): 193-198.
30. Xu Z, Li F, Xin Y, et al. Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis. Respir Res, 2024, 25(1): 410.
31. 付玉芬, 牟婷, 何翔, 等. 慢性阻塞性肺疾病頻繁急性加重的危險因素分析和預測模型構建. 中國醫學科學院學報, 2024, 46(4): 519-527.
32. Francis NA, Gillespie D, White P, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT. Health Technol Assess, 2020, 24(15): 1-108.
33. 胡小燕, 徐鑲懷, 鄭曉, 等. 血清內皮細胞特異性分子 1 與降鈣素原聯合檢測在慢性阻塞性肺疾病急性加重細菌感染中的臨床意義. 海軍軍醫大學學報, 2023, 44(8): 989-993.
34. 劉丹, 范惠君, 武亞莉, 等. 不同通氣方式對急性加重慢性阻塞性肺疾病患者呼吸道病毒分布及預后的影響. 中國病原生物學雜志, 2021, 16(7): 822-825.
35. 方晗語, 陳琳雯, 馮沁祺, 等. 基于 VOSviewer 軟件的中醫藥治療慢性阻塞性肺疾病急性加重期文獻計量學分析. 中國中醫基礎醫學雜志, 2022, 28(2): 243-246, 259.
36. 陳艷, 李曉梅. 老年 COPD 患者急性加重期并發呼吸衰竭危險因素及風險模型構建. 中國老年學雜志, 2022, 42(22): 5478-5480.
37. Marriott E, Singanayagam A, El-Awaisi J. Inflammation as the nexus: exploring the link between acute myocardial infarction and chronic obstructive pulmonary disease. Front Cardiovasc Med, 2024, 11: 1362564.
38. Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med, 2020, 41(3): 421-438.
39. 余群, 歐陽麗. 痰熱清注射液對痰濁壅肺型慢性阻塞性肺疾病急性加重期患者肺血管阻力和氧化應激指標的影響. 中國中醫基礎醫學雜志, 2019, 25(10): 1380-1382, 1403.
40. Yu S, Zhang H, Wan L, et al. The association between the respiratory tract microbiome and clinical outcomes in patients with COPD. Microbiol Res, 2023, 266: 127244.
41. Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease. Respir Res, 2019, 20(1): 113.

West China Medical Journal

Research status and hotspot analysis of acute exacerbation of chronic obstructive pulmonary disease based on bibliometrics

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content